Elan (ELN) and Biogen (BIIB) Sink After Disclosing Two Additional TYSABRI-Related PML Cases
Tweet
Share
E-mailGet Alerts ELN Hot Sheet
Join SI Premium – FREE
Elan Corporation (NYSE: ELN) and Biogen Idec (Nasdaq: BIIB) are down 34% and 15%, respectively, following disclosing that they notified relevant regulatory agencies of two confirmed cases of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with TYSABRI in the commercial setting.
Both PML cases were in the European Union. One patient is clinically stable and ambulatory at home and the other is currently hospitalized.
PML is a rare and often fatal disease that is characterized by progressive damage or inflammation of the brain.
Both PML cases were in the European Union. One patient is clinically stable and ambulatory at home and the other is currently hospitalized.
PML is a rare and often fatal disease that is characterized by progressive damage or inflammation of the brain.
You May Also Be Interested In
- Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
- FDA clears path for Protagenic's PT00114 anxiety drug IND submission
- Creative Medical completes enrollment in ADAPT back pain trial
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
